We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.


Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App

QuidelOrtho Highlights Innovative Point-of-Care Diagnostic Solutions

By LabMedica International staff writers
Posted on 21 May 2023
Print article
Image: The Savanna automated sample-to-result multiplex RT-PCR testing platform (Photo courtesy of QuidelOrtho)
Image: The Savanna automated sample-to-result multiplex RT-PCR testing platform (Photo courtesy of QuidelOrtho)

QuidelOrtho Corporation (San Diego, CA, USA) is highlighting the latest advances in laboratory testing and point-of-care diagnostics at the Euromedlab Congress in Rome. The company is demonstrating how effectively combining point-of-care and laboratory testing can enhance patient care and improve overall healthcare outcomes. QuidelOrtho’s advanced lab management tools and expertise can help labs streamline their workflow, automate operations, and efficiently analyze data, thereby enhancing overall efficiency without compromising on quality.

At EuroMedLab Rome 2023, the company is demonstrating Savanna – a true sample-to-result point-of-care multiplex molecular solution. The cutting-edge system can accurately and simultaneously test for SARS-CoV-2, Flu A, Flu B, and RSV on a panel within 20 minutes. Besides delivering rapid results, the RVP4 also delivers superior clinical performance and possesses the capability to detect SARS-CoV-2 variants. Additionally, QuidelOrtho is demonstrating how its Vitros XT 7600 Integrated System can boost lab efficiency, offering a wide-ranging menu of over 160 assays, thus future-proofing labs and preparing them for potential Vitros Automation incorporation. This system is also time-efficient, with a first-pass yield of 96.5% and incorporates E-Connectivity Technology for uninterrupted operation. The company's innovative waterless system further maximizes lab space and enhances productivity.

Among QuidelOrtho’s innovative point-of-care solutions being featured at the industry event is the TriageTrue High Sensitivity Troponin I Test. This revolutionary test empowers medical professionals to make informed decisions that lead to better patient outcomes and overall improved healthcare efficiency. The test merges ER and lab testing, delivering high diagnostic precision with results available in under 20 minutes. The quick results can expedite patient handling, minimize hospital stay duration, and enhance ED throughput. In addition, QuidelOrtho is participating in the Euromedlab 2023 Satellite Meeting - Point-of-Care Testing: Home, Hospital and Beyond event. The company’s Vendor Talk by Dr. Holger Gundelach, Head of EMEA POC-IA Business Unit and Clinical Value at QuidelOrtho, on "The time is now – Accelerate patient management at the point-of-care" will be providing valuable insights and exploring the future of point-of-care testing.

Related Links:
QuidelOrtho Corporation 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic ELISA Workstation

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.